Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 22, 2018
Pharmacy Choice - Pharmaceutical News - FDA Approves Benralizumab for Severe Asthma [All Iraq News Agency (AIN)] - March 22, 2018

Pharmacy News Article

 11/16/17 - FDA Approves Benralizumab for Severe Asthma [All Iraq News Agency (AIN)]

The FDA has approved AstraZeneca`s biologic drug benralizumab (Fasenra) for the add-on maintenance treatment of patients age 12 years and over with severe asthma with an eosinophilic phenotype, the drugmaker announced late Tuesday.

Approval was based on pivotal trials showing up to a 51% reduction in the annual asthma exacerbation rate versus placebo in patients with uncontrolled, severe asthma and high levels of eosinophilia. The drug also showed an overall adverse event profile similar to that of placebo in the trials, and users had median 75% reductions in daily oral corticosteroid use.

Benralizumab becomes the first approved monoclonal antibody with an 8-week maintenance dosing schedule, following three initial doses given every 4 weeks.

It`s the first approved drug that targets the interleukin-5 receptor. The two other IL-5 biologics approved by the FDA for severe, uncontrolled asthma GlaxoSmithKline`s mepolizumab (Nucala) and Teva`s reslizumab (Cinquair) both target the circulating IL-5 protein.

Trial results showed that benralizumab injections given once every 4 or 8 weeks decreased eosinophil counts, reduced asthma exacerbations, and improved lung function in patients with uncontrolled asthma with persistent eosinophilia.

In a press statement, AstraZeneca announced that benralizumab will be available for patients in the United States "within the coming weeks."

(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Mar 22: Treatment of Parkinson's Disease and Comorbid Conditions
Mar 25: Alternatives and Complements to Prescription Pain Management
Mar 26: Management of Alcohol Use Disorders
Mar 27: Pharmacy & the Opioid Crisis
Mar 28: Medication Adherence: To Take or Not to Take…That is the Problem
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement